PPT-GZR + EBR

CWORTHY Study Part C grazoprevir elbasvir  RBV in genotype 1b GZR EBR RBV N 30 N 31 Design W8 CWORTHYC Vierling JM EASL 2015 Abs P0769 gt 18 years HCV genotype 1b. Solution Usingseparationofvariables,wearriveattheradialequation(asinlecture),h2 2md2 dr2+2 rd dr+h2l(l+1) 2mr2+V(r)R(r)=EbR(r);wherelistheangularmomentumquantumnumberandm=469:4MeVisthereducedm ABOUT BEYOND BRICKS EBR. Community-driven and community-led. Supported. by the School System. A forum for ALL voices. Supporting Organizations. The . following organizations have been integral in designing . Design. C-SCAPE . Study. : . grazoprevir. ± . elbasvir. ± RBV . in . genotypes. 2, 4, 5 or 6. Treatment-naïve . Genotype 2. , 4, 5, 6. Non-cirrhotic, . HCV . monoinfected. Brown . A. . . J . Hepatol. Design. C-SCAPE . Study. : . grazoprevir. ± . elbasvir. ± RBV . in . genotypes. 2, 4, 5 or 6. Treatment-naïve . Genotype 2. , 4, 5, 6. Non-cirrhotic, . HCV . monoinfected. Brown . A. . . J . Hepatol. Poison Look - Alikes: - 1 7 2013 Tips to Prevent Accidental Poisoning at All Ages We often think of poisoning as something that happens to small children, but it’s also easy for adults to mix u . +/- Ribavirin in HCV Genotype 1, 4 or 6. C-EDGE Treatment Experienced (TE). Phase 3. . Treatment. . Experienced. Kwo. P, . et al. . EASL 2015. Abstract P0886.. Source: . Kwo. P et al. EASL 2015. Abstract P0886.. + . Grazoprevir. +/- Ribavirin in . Treatment-Naïve HCV . GT 2, 4, 5, or 6. C-SCAPE. Phase . 2 . Treatment. . Naïve. Brown A, . et al. . EASL 2015; Abstract P0771.. Source: Brown A, et al. EASL 2015; Abstract P0771.. 6; 386:1537-45. C-SURFER Study: . grazoprevir. . + . elbasvir. . in genotype 1 with chronic kidney disease. N = 111. GZR + EBR. Placebo. GZR + EBR (Intensive PK). N = 113. N = 11. GZR/EBR. W. 12. W16. N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. > . 18 years. HCV infection. G. enotype 1 or 4. Failure to a prior therapy with . SOF ± RBV + (SMV or DCV or LDV) . with documented presence of . NS5A or NS3 RASs at failure . in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. * Liver biopsy or . Fibroscan. ≤. 12.5 . kPa. or . Fibrosure. ®. . <. 0.48 + APRI . ≤ 1. Objective. Primary endpoint: SVR. 12 . (HCV RNA < 15 IU/mL), full analysis set ≥ 1 dose of study drug. 6; 386:1537-45. C-SURFER Study: . grazoprevir. . + . elbasvir. . in genotype 1 with chronic kidney disease. N = 111. GZR + EBR. Placebo. GZR + EBR (Intensive PK). N = 113. N = 11. GZR/EBR. W. 12. W16. By. Dr. . Amjed. Hassan. Midbrain. Gross. . A. . ppearanc. e. of. . M. . i. . dbrai. . n:. •. •. •. connects. the. . pons. . and. cerebel. . l. . um. . wi. . th. . the. f. . orebrai. C-WORTHY/D. GZR + EBR + RBV. GZR + EBR + RBV. N = 21. N = 20. Design. W12. W18. SVR. 12. >. 18 years. HCV genotype . 3. HCV RNA ≥ 10 000 IU/mL. Treatment naïve . No cirrhosis. No HBV or HIV co-infection.